Monoamine involvement in the antidepressant-like effect of β-caryophyllene. - GreenMedInfo Summary
Monoamine Involvement in the Antidepressant-Like Effect of β-Caryophyllene.
CNS Neurol Disord Drug Targets. 2018 Apr 20. Epub 2018 Apr 20. PMID: 29676236
Danillo Ramos Oliveira
This study was conducted to evaluate the antidepressant-like activity of sesquiterpene compoundβ-caryophyllene (BCP) for the possible contribution of the monoamine and hippocampal levels of brain-derived neurotrophic factor (BDNF). Male albino Swiss mice were subjected to the forced swimming test after acute treatment and to the tail suspension test after repeated treatment. Hippocampal levels of BDNF were assayed by enzyme-linked immunosorbent assay. The anti-immobility effect of BCP was reverted by pretreatment with inhibitor of catecholamines α-methyl-p-tyrosine (100 mg/kg, i.p.), α-adrenergic antagonist yohimbine (1 mg/kg, i.p.), and β-adrenergic antagonist propranolol (2 mg/kg,i.p.), but not by pretreatment with either α1-adrenergic antagonist prazosin (1 mg/kg, i.p.) or 5-HT1A antagonist NAN-190 (0.5 mg/kg, i.p.), thereby suggesting the involvement of the catecholaminergic system, but not of the 5-HT1A serotonergic receptor, in BCP's antidepressive-like activity. Furthermore, BCP increased BDNF levels in the hippocampus after 14 d of treatment. No treatments in this study altered locomotor activity in the open ﬁeld test. This study provides a new mechanism of BCP-induced antidepressant-like effect mediated by the central catecholaminergic neurotransmitter system that could be a candidate for clinical tests of new treatments for depressive disorders.